Does Rallies show Form 4 insider transactions for EXAS?

Yes. Rallies tracks EXAS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EXAS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EXAS. It does not provide personalized investment advice.

EXAS (Exact Sciences Corp) Stock Analysis - Insider Trades

Exact Sciences Corp (EXAS) is a publicly traded Healthcare sector company. As of May 21, 2026, EXAS trades at $104.91 with a market cap of $20.03B and a P/E ratio of -95.37. EXAS moved -0.02% today. Year to date, EXAS is +56.63%; over the trailing twelve months it is +136.92%. Its 52-week range spans $38.81 to $104.98. Analyst consensus is buy with an average price target of $103.18. Rallies surfaces EXAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EXAS stock inside the company?

Recent EXAS insider activity includes ORVILLE JACOB A sold 5.00K, Herriott James sold 1.00K, Herriott James sold 1.50K, Baranick Brian sold 2.86K, and Zanotti Katherine S sold 12.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EXAS Key Metrics

Key financial metrics for EXAS
Metric	Value
Price	$104.91
Market Cap	$20.03B
P/E Ratio	-95.37
EPS	$-1.10
Dividend Yield	0.00%
52-Week High	$104.98
52-Week Low	$38.81
Volume	21.56M
Avg Volume	0
Revenue (TTM)	$3.25B
Net Income	$-207.95M
Gross Margin	69.69%

Recent EXAS Insider Trades

ORVILLE JACOB A sold 5.00K (~$375.00K) on Nov 19, 2025.
Herriott James sold 1.00K (~$70.00K) on Nov 19, 2025.
Herriott James sold 1.50K (~$105.12K) on Nov 4, 2025.
Baranick Brian sold 2.86K (~$200.29K) on Nov 4, 2025.
Zanotti Katherine S sold 12.00K (~$780.00K) on Oct 24, 2025.

Latest EXAS News

Abbott Finalizes $23 Billion Exact Sciences Acquisition to Control Cologuard Tests — Mar 24, 2026
Exact Sciences Posts Forward P/E 71.29 and Wins Third Gallup Workplace Award — Mar 4, 2026
Quanterix Q4 revenue jumps 25% to $43.9M, places 38 instruments — Mar 2, 2026
Exact Sciences Shareholders Approve Abbott Merger, Reject Executive Pay Plan — Feb 23, 2026
Exact Sciences Stockholders Approve Abbott Acquisition with Over 80% Vote — Feb 20, 2026

EXAS Analyst Consensus

41 analysts cover EXAS: 0 strong buy, 22 buy, 17 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $103.18.

Common questions about EXAS

Who is trading EXAS stock inside the company?: Recent EXAS insider activity includes ORVILLE JACOB A sold 5.00K, Herriott James sold 1.00K, Herriott James sold 1.50K, Baranick Brian sold 2.86K, and Zanotti Katherine S sold 12.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EXAS?: Yes. Rallies tracks EXAS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EXAS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EXAS. It does not provide personalized investment advice.